Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet

Michele Baccarani, Jorge Cortes, Fabrizio Pane, Dietger Niederwieser, Giuseppe Saglio, Jane Apperley, Francisco Cervantes, Michael Deininger, Alois Gratwohl, François Guilhot, Andreas Hochhaus, Mary Horowitz, Timothy Hughes, Hagop Kantarjian, Richard Larson, Jerald Radich, Bengt Simonsson, Richard T. Silver, John Goldman, Rudiger Hehlmann

Research output: Contribution to journalReview article

Abstract

Purpose: To review and update the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia with imatinib and second-generation tyrosine kinase inhibitors (TKIs), including monitoring, response definition, and first- and second-line therapy. Methods: These recommendations are based on a critical and comprehensive review of the relevant papers up to February 2009 and the results of four consensus conferences held by the panel of experts appointed by ELN in 2008. Results: Cytogenetic monitoring was required at 3, 6, 12, and 18 months. Molecular monitoring was required every 3 months. On the basis of the degree and the timing of hematologic, cytogenetic, and molecular results, the response to first-line imatinib was defined as optimal, suboptimal, or failure, and the response to second-generation TKIs was defined as suboptimal or failure. Conclusion: Initial treatment was confirmed as imatinib 400 mg daily. Imatinib should be continued indefinitely in optimal responders. Suboptimal responders may continue on imatinb, at the same or higher dose, or may be eligible for investigational therapy with second-generation TKIs. In instances of imatinib failure, second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.

Original languageEnglish (US)
Pages (from-to)6041-6051
Number of pages11
JournalJournal of Clinical Oncology
Volume27
Issue number35
DOIs
StatePublished - Dec 10 2009
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Cytogenetics
Investigational Therapies
Hematopoietic Stem Cell Transplantation
Transplantation
Imatinib Mesylate
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chronic myeloid leukemia : An update of concepts and management recommendations of European LeukemiaNet. / Baccarani, Michele; Cortes, Jorge; Pane, Fabrizio; Niederwieser, Dietger; Saglio, Giuseppe; Apperley, Jane; Cervantes, Francisco; Deininger, Michael; Gratwohl, Alois; Guilhot, François; Hochhaus, Andreas; Horowitz, Mary; Hughes, Timothy; Kantarjian, Hagop; Larson, Richard; Radich, Jerald; Simonsson, Bengt; Silver, Richard T.; Goldman, John; Hehlmann, Rudiger.

In: Journal of Clinical Oncology, Vol. 27, No. 35, 10.12.2009, p. 6041-6051.

Research output: Contribution to journalReview article

Baccarani, M, Cortes, J, Pane, F, Niederwieser, D, Saglio, G, Apperley, J, Cervantes, F, Deininger, M, Gratwohl, A, Guilhot, F, Hochhaus, A, Horowitz, M, Hughes, T, Kantarjian, H, Larson, R, Radich, J, Simonsson, B, Silver, RT, Goldman, J & Hehlmann, R 2009, 'Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet', Journal of Clinical Oncology, vol. 27, no. 35, pp. 6041-6051. https://doi.org/10.1200/JCO.2009.25.0779
Baccarani, Michele ; Cortes, Jorge ; Pane, Fabrizio ; Niederwieser, Dietger ; Saglio, Giuseppe ; Apperley, Jane ; Cervantes, Francisco ; Deininger, Michael ; Gratwohl, Alois ; Guilhot, François ; Hochhaus, Andreas ; Horowitz, Mary ; Hughes, Timothy ; Kantarjian, Hagop ; Larson, Richard ; Radich, Jerald ; Simonsson, Bengt ; Silver, Richard T. ; Goldman, John ; Hehlmann, Rudiger. / Chronic myeloid leukemia : An update of concepts and management recommendations of European LeukemiaNet. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 35. pp. 6041-6051.
@article{ba111838e4d848f2bfecc50ce5d24604,
title = "Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet",
abstract = "Purpose: To review and update the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia with imatinib and second-generation tyrosine kinase inhibitors (TKIs), including monitoring, response definition, and first- and second-line therapy. Methods: These recommendations are based on a critical and comprehensive review of the relevant papers up to February 2009 and the results of four consensus conferences held by the panel of experts appointed by ELN in 2008. Results: Cytogenetic monitoring was required at 3, 6, 12, and 18 months. Molecular monitoring was required every 3 months. On the basis of the degree and the timing of hematologic, cytogenetic, and molecular results, the response to first-line imatinib was defined as optimal, suboptimal, or failure, and the response to second-generation TKIs was defined as suboptimal or failure. Conclusion: Initial treatment was confirmed as imatinib 400 mg daily. Imatinib should be continued indefinitely in optimal responders. Suboptimal responders may continue on imatinb, at the same or higher dose, or may be eligible for investigational therapy with second-generation TKIs. In instances of imatinib failure, second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.",
author = "Michele Baccarani and Jorge Cortes and Fabrizio Pane and Dietger Niederwieser and Giuseppe Saglio and Jane Apperley and Francisco Cervantes and Michael Deininger and Alois Gratwohl and Fran{\cc}ois Guilhot and Andreas Hochhaus and Mary Horowitz and Timothy Hughes and Hagop Kantarjian and Richard Larson and Jerald Radich and Bengt Simonsson and Silver, {Richard T.} and John Goldman and Rudiger Hehlmann",
year = "2009",
month = "12",
day = "10",
doi = "10.1200/JCO.2009.25.0779",
language = "English (US)",
volume = "27",
pages = "6041--6051",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "35",

}

TY - JOUR

T1 - Chronic myeloid leukemia

T2 - An update of concepts and management recommendations of European LeukemiaNet

AU - Baccarani, Michele

AU - Cortes, Jorge

AU - Pane, Fabrizio

AU - Niederwieser, Dietger

AU - Saglio, Giuseppe

AU - Apperley, Jane

AU - Cervantes, Francisco

AU - Deininger, Michael

AU - Gratwohl, Alois

AU - Guilhot, François

AU - Hochhaus, Andreas

AU - Horowitz, Mary

AU - Hughes, Timothy

AU - Kantarjian, Hagop

AU - Larson, Richard

AU - Radich, Jerald

AU - Simonsson, Bengt

AU - Silver, Richard T.

AU - Goldman, John

AU - Hehlmann, Rudiger

PY - 2009/12/10

Y1 - 2009/12/10

N2 - Purpose: To review and update the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia with imatinib and second-generation tyrosine kinase inhibitors (TKIs), including monitoring, response definition, and first- and second-line therapy. Methods: These recommendations are based on a critical and comprehensive review of the relevant papers up to February 2009 and the results of four consensus conferences held by the panel of experts appointed by ELN in 2008. Results: Cytogenetic monitoring was required at 3, 6, 12, and 18 months. Molecular monitoring was required every 3 months. On the basis of the degree and the timing of hematologic, cytogenetic, and molecular results, the response to first-line imatinib was defined as optimal, suboptimal, or failure, and the response to second-generation TKIs was defined as suboptimal or failure. Conclusion: Initial treatment was confirmed as imatinib 400 mg daily. Imatinib should be continued indefinitely in optimal responders. Suboptimal responders may continue on imatinb, at the same or higher dose, or may be eligible for investigational therapy with second-generation TKIs. In instances of imatinib failure, second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.

AB - Purpose: To review and update the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia with imatinib and second-generation tyrosine kinase inhibitors (TKIs), including monitoring, response definition, and first- and second-line therapy. Methods: These recommendations are based on a critical and comprehensive review of the relevant papers up to February 2009 and the results of four consensus conferences held by the panel of experts appointed by ELN in 2008. Results: Cytogenetic monitoring was required at 3, 6, 12, and 18 months. Molecular monitoring was required every 3 months. On the basis of the degree and the timing of hematologic, cytogenetic, and molecular results, the response to first-line imatinib was defined as optimal, suboptimal, or failure, and the response to second-generation TKIs was defined as suboptimal or failure. Conclusion: Initial treatment was confirmed as imatinib 400 mg daily. Imatinib should be continued indefinitely in optimal responders. Suboptimal responders may continue on imatinb, at the same or higher dose, or may be eligible for investigational therapy with second-generation TKIs. In instances of imatinib failure, second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.

UR - http://www.scopus.com/inward/record.url?scp=73349122639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349122639&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.25.0779

DO - 10.1200/JCO.2009.25.0779

M3 - Review article

C2 - 19884523

AN - SCOPUS:73349122639

VL - 27

SP - 6041

EP - 6051

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 35

ER -